Vytorin (ezetimibe; simvastatin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	/IBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESCRIFOLLOWING LINK: PRIMETHERAPEUTICS.COM,	SHT (IN/CM): WEIGH BER, YOU WILL NEED TO SUBMIT A PHI DISCLO (NOPP) EESENTATIVE (IF APPLICABLE):	SURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE	
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
□ NEW THERAPY □ RENEWAL I		IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):			

Prime THERAPEUTICS*

Continued on next page.

Vytorin (ezetimibe; simvastatin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
3. REQUIRED CLINICAL INFORMATION	: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.				
Clinical Information:				
Has the patient had a trial with a gene	eric statin plus Zetia taken concurrently	as individual products? Yes No		
Did the matient develop developed				
Did the patient develop dysphagia as a result of such prior concurrent treatment? Yes No				
Documentation must be provided.				
If no, provide rationale explaining why	y the patient was unable to continue the	erany:		
protide rationale explaining time	, the patient has an able to continue the			
Is there medical rationale explaining why treatment with Vytorin is necessary over that of a generic statin				
plus Zetia? Yes No Please provide supporting documentation.				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the				
physician feels is important to this rev	iew?			
Discourse Not all describes		harde stade at least all the stade		
information is received.	e covered on all plans. This request may	be defiled unless all required		
	n provided is true and accurate to the be	st of my knowledge. Lunderstand that		
	p or its designees may perform a routine	,		
	curacy of the information reported on thi	•		
	, , , ,			
Prescriber Signature or Electronic I.D.	Verification:	Date:		
	ompanying this transmission contain confidential			
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)				
of these documents is strictly profibited. If you	nave received this information in error, please no	in y the sender infinediately (via return PAA)		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.